# Beyond Hypomethylating Agents: Novel Therapies and Targeted Approaches

## TL;DR

This paper reviews current and emerging treatments for myelodysplastic syndromes, emphasizing the need for precision medicine and better patient selection to improve outcomes.

## Contribution

The paper highlights novel therapies and targeted approaches for MDS, focusing on the limitations of current treatments and the potential of precision medicine.

## Key findings

- Hypomethylating agents provide only modest survival benefits for high-risk MDS.
- Immune checkpoint inhibitors like ipilimumab and durvalumab have not shown definitive results in clinical trials.
- Drugs like luspatercept and imetelstat show promise for lower-risk MDS, while agents like pevonedistat and magrolimab are being explored for high-risk MDS.

## Abstract

Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic diseases sharing ineffective hematopoiesis, cytopenias, and a high risk of evolution to acute myeloid leukemia (AML). The current MDS classification systems, such as the International Consensus Classification (ICC) and the WHO 2022 classification, have incorporated molecular and cytogenetic markers to improve the stratification of risk and guide therapy. However, treatment options for high-risk MDS (HR-MDS) remain limited, with hypomethylating agents (HMAs) providing only modest survival benefits. Emerging treatments such as immune checkpoint blockade and novel targeted therapies could further improve patient outcomes. While early excitement was significant, clinical trials of the immune checkpoint inhibitors (ICIs) ipilimumab and durvalumab have produced no definitive results, highlighting the need for better patient selection and combination regimens. Emerging drugs luspatercept and imetelstat have been suggested for lower-risk MDS (LR-MDS) by promoting transfusion independence and global hematologic response. In contrast, exploratory agents such as pevonedistat, magrolimab, and sabatolimab are under further investigation for HR-MDS. The future of MDS treatment currently addresses precision medicine, in which molecular characterization guides therapeutic options. Identification of predictive biomarkers for response to targeted therapies and immunotherapies is crucial to optimize patient outcomes. An integrated, patient-centered approach combining genomics, novel therapeutics, and immunomodulation is therefore essential to address the current needs in MDS management.